
12-year results of the phase III SOFT trial show a maintained disease-free survival benefit
12-year results of the phase III SOFT trial show a maintained disease-free survival benefit
12-year results of the phase III SOFT trial show a maintained disease-free survival benefit
This KEYTRUDA Combination Is Approved for High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
New COVID-19 Resources from FORCE
Over 20 Years Fighting For Those Who Came Before and Those Who Will Come After
We Need Your Support Today!